Galactosemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Galactosemia represents a collection of uncommon hereditary metabolic disorders. These conditions are characterized by difficulties metabolizing galactose, leading to a spectrum of manifestations. This spectrum includes a severe and life-threatening form known as classic galactosemia, a rarer milder form referred to as galactokinase deficiency, which leads to cataract formation, and an exceedingly rare type called galactose epimerase deficiency, varying in severity and resembling the severe form of classic galactosemia. The underlying genetic mutations responsible for the various types of galactosemia occur in three genes: GALT, GALK1, and GALE. These genes, located on different chromosomes (9p13, 17q24, and 1p36), provide instructions for producing enzymes crucial for galactose metabolism. The dysfunction of these enzymes disrupts the Leloir galactose degradation pathway. All these disorders follow an autosomal recessive inheritance pattern. In infants, particularly those with classic galactosemia, common symptoms include difficulties in feeding, inadequate weight gain, and growth, lethargy, and jaundice. The less severe galactokinase deficiency mainly leads to cataracts, while other typical galactosemia signs are absent. The highly rare galactose epimerase deficiency presents a variable clinical picture, encompassing typical galactosemia symptoms like hypotonia, poor feeding, vomiting, weight loss, jaundice, and additional complications such as impaired growth, cognitive deficits, and cataracts. Managing galactosemia involves strictly avoiding lactose and galactose-containing foods. Individuals with galactosemia cannot effectively digest such foods. There is no available chemical or drug replacement for the missing enzyme. If an infant is diagnosed with galactosemia, they are typically switched to a formula devoid of galactose.

·       Galactosemia is a rare disorder, with approximately 80 newborns in the USA being diagnosed each year. About 3,000 people in the USA are affected by this condition.

 

Thelansis’s “Galactosemia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Galactosemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Galactosemia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Galactosemia Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Galactosemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Galactosemia, Galactosemia market outlook, Galactosemia competitive landscape, Galactosemia market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)